| Literature DB >> 35806881 |
Shekhar Saha1,2, Ralitsa Mladenova1, Caroline Radner1,2, Konstanze Maria Horke1,2, Joscha Buech1,2, Philipp Schnackenburg1,2, Ahmad Ali1,2, Sven Peterss1,2, Gerd Juchem1,2, Maximilian Luehr1,3, Christian Hagl1,2, Dominik Joskowiak1,2.
Abstract
OBJECTIVES: The objective of this study was to compare the long-term outcomes and health-related quality of life (HRQOL) of patients following surgery for infective native valve endocarditis (NVE) and prosthetic valve endocarditis (PVE).Entities:
Keywords: health-related quality of life; infective endocarditis; valve replacement
Year: 2022 PMID: 35806881 PMCID: PMC9267565 DOI: 10.3390/jcm11133599
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Baseline parameters. Data are presented as medians (25–75th percentiles) or absolute numbers (percentages). BMI: body mass index, COPD: chronic obstructive pulmonary disease, LVEF: left ventricular ejection fraction, and PVE: prosthetic valve endocarditis.
| NVE | PVE | ||
|---|---|---|---|
| Age (years) | 64 (52–74) | 69 (60–75) | <0.001 |
| BMI (kg/m2) | 24.7 (22.6–23.6) | 25.6 (23.6–27.8) | 0.033 |
| BMI > 25 kg/m2 | 223 (47.1) | 106 (55.8) | 0.039 |
| Male (%) | 341 (72.1) | 160 (84.2) | 0.001 |
| EuroSCORE II (%) | 23.2 (14.7–36.3) | 51.5 (39.0–67.2) | <0.001 |
| NYHA class | 0.005 | ||
|
NYHA I–II | 159 (33.6) | 43 (22.6) | |
|
NYHA III–IV | 314 (66.4) | 147 (77.4) | |
| LVEF | 0.018 | ||
|
≥50% | 201 (42.5) | 65 (34.2) | |
|
31–49% | 251 (53.1) | 107 (56.3) | |
|
≤30% | 21 (4.4) | 18 (9.5) | |
| Arterial hypertension (%) | 297 (62.8) | 151 (79.5) | <0.001 |
| Hyperlipoproteinemia (%) | 116 (24.5) | 102 (53.7) | <0.001 |
| Chronic kidney disease (%) | 162 (34.2) | 70 (36.8) | 0.527 |
| Dialysis (%) | 25 (5.3) | 14 (7.4) | 0.303 |
| Creatinine clearance (mL/min) | 63 (42–87) | 53 (39–69) | <0.001 |
| Creatinine clearance < 50 mL/min | 165 (34.9) | 85 (44.7) | 0.018 |
| Smokers (%) | 96 (20.3) | 52 (27.4) | 0.048 |
| COPD (%) | 46 (9.7) | 28 (14.7) | 0.061 |
| Coronary artery disease (%) | 138 (29.2) | 76 (40.0) | 0.007 |
| Diabetes mellitus (%) | 88 (18.6) | 45 (23.7) | 0.140 |
| Pacemaker (%) | 13 (2.8) | 23 (12.1) | <0.001 |
| Peripheral vascular disease (%) | 34 (7.2) | 17 (9.0) | 0.425 |
| Prior neurological disorder (%) | 116 (24.5) | 52 (27.4) | 0.552 |
| Preoperative cerebral emboli (%) | 107 (22.6) | 48 (25.3) | 0.456 |
| Intravenous drug use (%) | 8 (1.7) | 3 (1.6) | 0.922 |
| Reoperations (%) | 29 (6.1) | 184 (96.8) | <0.001 |
| Time to PVE (years) | - | 3.0 (0.6–7.6) | - |
| Early PVE (%) | - | 47 (7.1) | - |
| Vegetations (%) | 355 (75.1) | 149 (78.4) | 0.455 |
Postoperative complications and outcomes. Data are presented as medians (25–75th percentiles) or absolute numbers (percentages). ECLS: extracorporeal life support, IABP: intra-aortic balloon pump, ICU: intensive care unit, LCOS: low cardiac output syndrome, and PMV: postoperative mechanical ventilation.
| Morbidities | NVE | PVE | |
|---|---|---|---|
| Adverse cerebrovascular events (%) | 105 (22.3) | 54 (28.4) | 0.106 |
| Severe bleeding with re-exploration (%) | 47 (10.0) | 35 (18.4) | 0.003 |
| Tracheostomy (%) | 30 (6.3) | 23 (12.1) | 0.012 |
| Pacemaker implantation (%) | 31 (6.6) | 48 (25.3) | 0.016 |
| Renal replacement therapy (%) | 39 (8.2) | 23 (12.1) | 0.123 |
| LCOS (%) | 51 (10.8) | 30 (15.8) | 0.088 |
| Septic shock (%) | 81 (17.1) | 50 (10.6) | 0.007 |
| ECLS support (%) | 19 (4.0) | 29 (15.3) | <0.001 |
| IABP (%) | 9 (1.9) | 5 (2.6) | 0.544 |
|
| |||
| Operative mortality (%) | 65 (13.7) | 41 (21.6) | 0.010 |
| Length of hospital stay (days) | 16 (8–26) | 20 (12–34) | 0.001 |
| Length of ICU stay (days) | 4 (2–7) | 5 (3–12) | <0.001 |
| ICU stay > 14 days (%) | 53 (11.2) | 42 (22.1) | 0.001 |
| ICU stay > 7 days (%) | 137 (30.0) | 72 (38.0) | 0.025 |
| Length of PMV (hours) | 13 (8–29) | 20 (12–34) | <0.001 |
|
| |||
| Recurrence (%) | 33 (7.0) | 17 (8.9) | 0.389 |
| Redo surgery for endocarditis (%) | 23 (4.9) | 5 (2.6) | 0.195 |
| Any surgical procedure (%) | 60 (12.7) | 27 (14.2) | 0.606 |
Results of the SF-36 survey. NVE: native valve endocarditis and PVE: prosthetic valve endocarditis. Data are presented as medians (25–75th percentiles).
| NVE | PVE | Standard | ||
|---|---|---|---|---|
| Physical functioning | 80 (63–95) | 75 (50–90) | 90 (60–95) | 0.005 |
| Role physical | 100 (25–100) | 63 (0–100) | 100 (50–100) | <0.001 |
| Bodily pain | 100 (62–100) | 84 (62–100) | 74 (51–100) | 0.001 |
| General health | 62 (46–72) | 59 (39–77) | 62 (45–77) | 0.600 |
| Vitality | 60 (40–75) | 55 (40–70) | 60 (45–75) | 0.135 |
| Social functioning | 88 (63–100) | 88 (63–100) | 100 (75–100) | <0.001 |
| Role emotional | 100 (33–100) | 100 (33–100) | 100 (100–100) | <0.001 |
| Mental health | 76 (64–88) | 76 (64–84) | 76 (64–88) | 0.678 |
| Physical summary score | 49 (40–55) | 45 (37–52) | 49 (36–55) | 0.315 |
| Mental summary score | 52 (35–57) | 49 (41–56) | 54 (49–58) | 0.005 |
a Kruskal–Wallis test.
Figure 1Kaplan–Meier survival curves for native valve endocarditis versus prosthetic valve endocarditis.